FIGURE 2.

Novel hot spots in tumor and TME, host, concomitant medications related to the efficacy and resistance of ICIs. ^∗The current classification methods are no longer limited to traditional methods, such as tumor immunogenicity or PD-L1 expression and tumor infiltrating lymphocytes (TILs) or characteristics of tumor tissue sections. Multiple omics analysis has also become a very promising method. # Germline genetic has recently become a research hotspot that affects the efficacy of immunotherapy, we only list a few gene polymorphisms directly related to ICIs resistance. $ There is controversy about the effects of the above-mentioned drugs on the efficacy of ICIs. ICIs, immune checkpoint inhibitors; PD, progressive disease; TME, tumor microenvironment.